These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 19129050)

  • 1. Waking up the sleepers: HIV latency and reactivation.
    Mok HP; Lever A
    J Formos Med Assoc; 2008 Dec; 107(12):909-14. PubMed ID: 19129050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between Measures of HIV Reactivation and Decline of the Latent Reservoir under Latency-Reversing Agents.
    Petravic J; Rasmussen TA; Lewin SR; Kent SJ; Davenport MP
    J Virol; 2017 May; 91(9):. PubMed ID: 28202759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current views on HIV-1 latency, persistence, and cure.
    Melkova Z; Shankaran P; Madlenakova M; Bodor J
    Folia Microbiol (Praha); 2017 Jan; 62(1):73-87. PubMed ID: 27709447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. From reactivation of latent HIV-1 to elimination of the latent reservoir: the presence of multiple barriers to viral eradication.
    Shan L; Siliciano RF
    Bioessays; 2013 Jun; 35(6):544-52. PubMed ID: 23613347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Underlying mechanisms of HIV-1 latency.
    Romani B; Allahbakhshi E
    Virus Genes; 2017 Jun; 53(3):329-339. PubMed ID: 28258391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of latency reversal agents in the cure of HIV: A review of current data.
    Bashiri K; Rezaei N; Nasi M; Cossarizza A
    Immunol Lett; 2018 Apr; 196():135-139. PubMed ID: 29427743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What can we do to reduce the viral reservoir in HIV-1-infected individuals?
    Pohlmeyer CW; Walker-Sperling VE; Blankson JN
    Future Microbiol; 2016 Jul; 11():839-42. PubMed ID: 27416850
    [No Abstract]   [Full Text] [Related]  

  • 8. Therapeutics for HIV-1 reactivation from latency.
    Sgarbanti M; Battistini A
    Curr Opin Virol; 2013 Aug; 3(4):394-401. PubMed ID: 23810462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Posttranscriptional Regulation of HIV-1 Gene Expression during Replication and Reactivation from Latency by Nuclear Matrix Protein MATR3.
    Sarracino A; Gharu L; Kula A; Pasternak AO; Avettand-Fenoel V; Rouzioux C; Bardina M; De Wit S; Benkirane M; Berkhout B; Van Lint C; Marcello A
    mBio; 2018 Nov; 9(6):. PubMed ID: 30425153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies.
    Colin L; Van Lint C
    Retrovirology; 2009 Dec; 6():111. PubMed ID: 19961595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV Replication and Latency in a Humanized NSG Mouse Model during Suppressive Oral Combinational Antiretroviral Therapy.
    Satheesan S; Li H; Burnett JC; Takahashi M; Li S; Wu SX; Synold TW; Rossi JJ; Zhou J
    J Virol; 2018 Apr; 92(7):. PubMed ID: 29343582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo.
    Søgaard OS; Graversen ME; Leth S; Olesen R; Brinkmann CR; Nissen SK; Kjaer AS; Schleimann MH; Denton PW; Hey-Cunningham WJ; Koelsch KK; Pantaleo G; Krogsgaard K; Sommerfelt M; Fromentin R; Chomont N; Rasmussen TA; Østergaard L; Tolstrup M
    PLoS Pathog; 2015 Sep; 11(9):e1005142. PubMed ID: 26379282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection.
    Tsai P; Wu G; Baker CE; Thayer WO; Spagnuolo RA; Sanchez R; Barrett S; Howell B; Margolis D; Hazuda DJ; Archin NM; Garcia JV
    Retrovirology; 2016 May; 13(1):36. PubMed ID: 27206407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel histone deacetylase inhibitors CG05 and CG06 effectively reactivate latently infected HIV-1.
    Choi BS; Lee HS; Oh YT; Hyun YL; Ro S; Kim SS; Hong KJ
    AIDS; 2010 Feb; 24(4):609-11. PubMed ID: 20154582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic Approaches to Eradicate Latent HIV-1 in Resting CD4+ T Cells.
    Sluis-Cremer N
    Curr Top Med Chem; 2016; 16(10):1191-7. PubMed ID: 26324046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Between a shock and a hard place: challenges and developments in HIV latency reversal.
    Zerbato JM; Purves HV; Lewin SR; Rasmussen TA
    Curr Opin Virol; 2019 Oct; 38():1-9. PubMed ID: 31048093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bryostatin-1 synergizes with histone deacetylase inhibitors to reactivate HIV-1 from latency.
    Pérez M; de Vinuesa AG; Sanchez-Duffhues G; Marquez N; Bellido ML; Muñoz-Fernandez MA; Moreno S; Castor TP; Calzado MA; Muñoz E
    Curr HIV Res; 2010 Sep; 8(6):418-29. PubMed ID: 20636281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maraviroc Is Associated with Latent HIV-1 Reactivation through NF-κB Activation in Resting CD4
    Madrid-Elena N; García-Bermejo ML; Serrano-Villar S; Díaz-de Santiago A; Sastre B; Gutiérrez C; Dronda F; Coronel Díaz M; Domínguez E; López-Huertas MR; Hernández-Novoa B; Moreno S
    J Virol; 2018 May; 92(9):. PubMed ID: 29444937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The challenge of finding a cure for HIV infection.
    Richman DD; Margolis DM; Delaney M; Greene WC; Hazuda D; Pomerantz RJ
    Science; 2009 Mar; 323(5919):1304-7. PubMed ID: 19265012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RNA-induced epigenetic silencing inhibits HIV-1 reactivation from latency.
    Méndez C; Ledger S; Petoumenos K; Ahlenstiel C; Kelleher AD
    Retrovirology; 2018 Oct; 15(1):67. PubMed ID: 30286764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.